Novacyt S.A.
(“Novacyt”, the “Company” or the “Group”)
Directorate change
Dr John Brown CBE appointed as Chairman
Paris, France, and Eastleigh and Manchester, UK – 26 September 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the appointment of Dr John Brown CBE as Chairman effective from 1 October 2024. Dr Brown was appointed Non-executive Director of Novacyt in September 2023 following the acquisition of Yourgene Health and will succeed James Wakefield, who is retiring from the Board having been Chairman since before the company joined AIM in 2017.
Dr Brown has over 38 years industry experience, which includes significant capital markets and board experience in the healthcare and life sciences sector. He is currently Chairman of Laverock Therapeutics Ltd and Calcivis Ltd, and until recently was Chairman of Synpromics Ltd, BioCity Group and the Cell and Gene Therapy Catapult. Previously, he was Chairman of Kyowa Kirin International plc, BTG plc, Axis-Shield plc, Touch Bionics Ltd and CXR Biosciences Ltd and Senior Non-Executive Director of Quantum Pharma plc. Dr Brown was appointed to the Board of Yourgene Health in July 2019 as a Non-executive Director and became Chairman in April 2022.
Dr John Brown CBE
Chairman of Novacyt S.A.
Lyn Rees, CEO of Novacyt, commented: “It is a pleasure to have John stepping into the role of Chairman at Novacyt. John has a proven track record of successfully building life sciences companies and his wealth of knowledge in capital markets and the life sciences sector will be important as we look to execute the strategic plan of the combined business.
“I would like to thank James for his contribution and leadership of Novacyt, especially navigating the business through the pandemic and its aftereffects. Under James’ tenure, the business has made a series of successful acquisitions, including Primerdesign and more recently Yourgene Health. James leaves the business in a strong financial position, with significant cash resources and a broad portfolio of molecular diagnostics products and services.”
Dr John Brown, Incoming Chairman said: “I am delighted to be appointed Chairman of Novacyt. The Group has a strong and diverse portfolio of differentiated molecular diagnostic products, established sales channels and a world-class team of experts. I look forward to continuing to work with Lyn and the rest of the Board as we drive the business through the next stage of development.”
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Contacts
|
Novacyt SA |
https://novacyt.com/investors |
|||
|
Lyn Rees, Chief Executive Officer |
Via Walbrook PR |
|||
|
Steve Gibson, Chief Financial Officer
|
|
|||
|
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) |
+44 (0)20 3470 0470 |
|||
|
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) |
|
|||
|
|
|
|||
|
Deutsche Numis (Joint Broker) |
+44 (0)20 7260 1000 |
|||
|
Freddie Barnfield / Duncan Monteith / Michael Palser |
|
|||
|
|
|
|||
|
Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit |
+33 (1) 42 22 10 10 [email protected] / [email protected] |
|||
|
|
|
|||
|
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Paul McManus / Phillip Marriage / Alice Woodings |
+44 (0)20 7933 8780 or [email protected] +44 (0)7796 794 663 / +44 (0)7980 541 893 +44 (0)7867 984 082 / +44 (0)7407 804 654 |
|||
About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
The Company is divided into three business segments:
|
Clinical |
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel |
|
Instrumentation |
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology · MyGo: real-time quantitative PCR (qPCR) instruments
|
|
Research Use Only |
Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) |
Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange’s AIM market (“NCYT”) and on the Paris Stock Exchange Euronext Growth (“ALNOV”).
For more information, please refer to the website: www.novacyt.com
END
BOALAMJTMTITBTI
